172 related articles for article (PubMed ID: 16477587)
1. An open-label study of escitalopram (Lexapro) for the treatment of 'Depression of Alzheimer's disease' (dAD).
Rao V; Spiro JR; Rosenberg PB; Lee HB; Rosenblatt A; Lyketsos CG
Int J Geriatr Psychiatry; 2006 Mar; 21(3):273-4. PubMed ID: 16477587
[TBL] [Abstract][Full Text] [Related]
2. The influence of educational information on depressed outpatients treated with escitalopram: a semi-naturalistic study.
Leinonen E; Niemi H
Nord J Psychiatry; 2007; 61(2):109-14. PubMed ID: 17454725
[TBL] [Abstract][Full Text] [Related]
3. Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany.
Möller HJ; Langer S; Schmauss M
Pharmacopsychiatry; 2007 Mar; 40(2):53-7. PubMed ID: 17447173
[TBL] [Abstract][Full Text] [Related]
4. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
Chokka P; Legault M
Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
Fantino B; Moore N; Verdoux H; Auray JP
Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
[TBL] [Abstract][Full Text] [Related]
6. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
Bech P; Andersen HF; Wade A
Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
[TBL] [Abstract][Full Text] [Related]
7. Mood and neuropsychological changes in women with midlife depression treated with escitalopram.
Wroolie TE; Williams KE; Keller J; Zappert LN; Shelton SD; Kenna HA; Reynolds MF; Rasgon NL
J Clin Psychopharmacol; 2006 Aug; 26(4):361-6. PubMed ID: 16855452
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
Olié JP; Tonnoir B; Ménard F; Galinowski A
Depress Anxiety; 2007; 24(5):318-24. PubMed ID: 17041922
[TBL] [Abstract][Full Text] [Related]
9. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
Montgomery SA; Möller HJ
Int Clin Psychopharmacol; 2009 May; 24(3):111-8. PubMed ID: 19357527
[TBL] [Abstract][Full Text] [Related]
10. Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'.
Rosenberg PB; Onyike CU; Katz IR; Porsteinsson AP; Mintzer JE; Schneider LS; Rabins PV; Meinert CL; Martin BK; Lyketsos CG;
Int J Geriatr Psychiatry; 2005 Feb; 20(2):119-27. PubMed ID: 15660424
[TBL] [Abstract][Full Text] [Related]
11. Escitalopram in the treatment of anxiety symptoms associated with depression.
Bandelow B; Andersen HF; Dolberg OT
Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
[TBL] [Abstract][Full Text] [Related]
15. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.
Pinto C; Trivedi JK; Vankar GK; Sharma PS; Narasimha V
J Indian Med Assoc; 2007 Jul; 105(7):364, 366, 368 passim. PubMed ID: 18178988
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
Schmitt L; Tonnoir B; Arbus C
Neuropsychobiology; 2006; 54(4):201-7. PubMed ID: 17337913
[TBL] [Abstract][Full Text] [Related]
17. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial.
Bretlau LG; Lunde M; Lindberg L; Undén M; Dissing S; Bech P
Pharmacopsychiatry; 2008 Mar; 41(2):41-7. PubMed ID: 18311683
[TBL] [Abstract][Full Text] [Related]
18. [Escitalopram: a chiral agent for treatment of depression].
Overlack M; Davids E; Gastpar M
Med Monatsschr Pharm; 2004 May; 27(5):148-51. PubMed ID: 15171592
[No Abstract] [Full Text] [Related]
19. [Severe forms of depression: the efficacy of escitalopram].
Spadone C
Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384
[TBL] [Abstract][Full Text] [Related]
20. The onset of effect for escitalopram and its relevance for the clinical management of depression.
Wade A; Friis Andersen H
Curr Med Res Opin; 2006 Nov; 22(11):2101-10. PubMed ID: 17076970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]